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INTRODUCTION 
The standard clinical practice of allogeneic bone mar-
row transplant (BMT) involves the transfer of hetero g e-
neous suspensions of cells that contain rare hematopoietic
stem cells (HSCs) and diff e rentiated blood cell types. In the
last several years it has become clear that although HSCs
a re the only cells that can regenerate hematopoiesis in a
myeloablated patient, other cells contained within the graft
contribute both negative and positive effects. The most
serious complication of allogeneic BMT, graft-vs.-host dis-
ease (GVHD) [1,2], is mediated by mature immune cells,
p a rticularly T cells. However, attempts to reduce GVHD
by depletion of T cells from bone marrow (BM) grafts
result in a higher incidence of engraftment failure [3–5], as
well as the loss of an effect against certain types of malig-
nancies, particularly leukemias [6,7]. The importance of
graft-vs.-tumor (GVT) reactivity as a therapeutic benefit of
allogeneic BMT has been amply shown in animal models
[6,7] and directly demonstrated in transplant patients with
relapsed chronic myelogenous leukemia (CML) when the
patients were induced into cytogenetic and molecular
remission following the infusion of allogeneic donor lym-
phocytes [8–10]. Although the majority of patients enter
remission following infusion of donor lymphocytes, the
remission is often accompanied by significant GVHD
[11,12]. Thus, an idealized approach to allogeneic BMT is
to transplant purified populations of hematopoietic cells
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ABSTRACT 
It is known that an important curative benefit of allogeneic bone marrow transplantation (BMT) in the treatment of
hematolymphoid malignancies is a graft-vs.-tumor (GVT) effect. GVT activity has been attributed to mature
immune cells contained within the graft because T-cell depletion of bone marrow results in increased rates of dis-
ease relapse post-transplantation. We previously demonstrated successful engraftment of highly purified hemato-
poietic stem cells (HSCs) transplanted across major histocompatibility complex (MHC) barriers in mice. In the
p resent study, we have developed a preclinical model of allogeneic HSC transplantation into lymphoma-inoculated
mice, allowing us to directly test whether purified HSCs have measurable GVT activity. We then perf o rm e d
c otransfer studies of HSCs with purified immune cells to identify which population(s) confers tumor protection and
the mechanism by which such cells suppress tumor growth. MHC-mismatched donor- recipient combinations were
studied. All of the GVT activity was contained in the CD81 cell fraction and, at the doses of CD81 cells tested,
tumor protection was separable from acute graft-vs.-host disease (aGVHD). Although there appears to be no func-
tional diff e rence between BM- and splenic-derived CD81 cells with re g a rd to GVT activity without aGVHD, this
was not the case for purified CD31 cells. CD31 cells derived from BM were tumor protective, whereas transplanta-
tion of equivalent doses of CD31 cells purified from spleen resulted in lethal GVHD. The mechanism by which the
G V T- c o n f e rring cells protect recipient mice from tumors was studied using immune defective mice as donors. We
found that an intact pathway of perforin-dependent cytolysis, as well as an intact Fas-ligand pathway, is re q u i red in
o rder to exert maximal anti-tumor activity.
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that have defined activities and that include HSCs and
m a t u re immune cells, which confer GVT activity without
causing GVHD. 
In prior studies from our laboratory, we developed the
methodologies to re p roducibly achieve engraftment of a
highly purified population of HSCs transplanted acro s s
allogeneic barriers in mice [13]. The HSC population was
originally defined by Spangrude, et al. [14] and is charac-
terized by the surface markers Thy-1 l oL i n– / l oS c a1. Thy-
1l oL i n– / l oS c a1 cells are capable of self-renewal, give rise to
all blood lineages, and have an ~2000-fold enriched ability
to radioprotect lethally irradiated mice transplanted acro s s
CD45 congenic barriers [14]. The analogous human HSC
population has been characterized and isolated [15], and its
activity has been demonstrated in autologous transplanta-
tion studies [16,17]. 
In the experiments re p o rted here we have developed a
model in which lymphoma-inoculated mice have persistent
tumor following syngeneic BMT in order to formally test
whether purified allogeneic HSCs have measurable GVT
a c t i v i t y. Furt h e r, we sought to determine the identity and
characteristics of the non-HSC populations that confer
significant GVT activity without causing GVHD. The
mouse B-cell lymphoma designated BCL1 was selected for
these experiments. BCL1 has been extensively studied and
is analogous to human prolymphocytic leukemia [18,19].
BALB/c mice are the known permissive hosts for BCL1
tumor growth, and even a single viable BCL1 cell trans-
f e rred into unmanipulated BALB/c mice results in pro-
g ressive disease and death in approximately 50% of the
recipients [20]. Following inoculation, the tumor first
homes to and grows in the spleen, causing massive
splenomegaly with later involvement of the lymph nodes,
BM, and peripheral blood [21,22]. The model we devel-
oped is a sensitive assay which has allowed us to identify
both the cells that predominate in the anti-BCL1 re s p o n s e
and the way in which such GVT- c o n f e rring cells may
function to suppress tumor growth. 
MATERIALS AND METHODS
Mouse strains
For the major histocompatibility complex (MHC)–mis-
matched experiments, 5–7-week-old C57BL/Ka.Thy1.1
(BA; H-2Db, Thy1.1) mice were used as HSC and BM allo-
geneic donors; 5–7-week-old BALB/c (H-2Dd, Thy1.2)
mice were used as BM syngeneic donors; and 7–10-week-
old BALB/c mice were used as recipients. The following
genetically engineered knockout mice bred onto the
C57BL background were used in some experiments as BM
donors: perforin knockout (C57BL/6-Pfpt m l S d z), inter-
leukin-2 (IL-2) knockout (C57BL/6-46J-Il-2t m l H o r), and
i n t e rf e ro n -g ( I F N -g) knockout (C57Bl/6-Ifngt m l Ts). The
Fas-ligand (FasL) mutant mice (B6Smn:Fasg l d) were also
used as donors in some experiments. Knockout mice were
obtained from the Jackson Laboratory (Bar Harbor, ME).
All other mice were bred at Stanford University in the
D e p a rtment of Comparative Medicine. All mice were
maintained in specific pathogen-free conditions under Nal-
gene filter-top cages in temperature - c o n t rolled and light
cycled ro o m s .
R a d i a t i o n
Recipient BALB/c mice were lethally irradiated (8 Gy)
by a 250-kV X-ray machine at 100 rad/min in two split
doses (4 Gy each) with a 3–4-hour interval. After irr a d i a-
tion, mice were maintained on antibiotic water containing
1 06 U/L of polymyxin B sulfate and 1 g/L of neomycin sulfate. 
B C L 1 tumor cells
B C L1 is a B-cell leukemia/lymphoma that expre s s e s
IgM, IgD, and class I and II MHC molecules on the cell
s u rface [18,23]. The tumor is maintained by in vivo p a s-
sage in unmanipulated BALB/c recipients. The BCL1
tumor cell line and the hybridoma 6A5 were kind gifts
f rom Dr. R. Levy (Stanford, CA). 
Bone marrow and hematopoietic stem cell
t r a n s p l a n t a t i o n
BM cells were obtained from donor mice by flushing
tibias and femurs with Hanks Balanced Salt Solution
(HBSS; Applied Scientific, San Francisco, CA) supple-
mented with 2% fetal calf serum (FCS; Gemini Bio-Pro d-
ucts, Calabasas, CA) using a 25-gauge needle and syringe.
The cells were washed once by centrifugation, counted,
and resuspended at the desired concentration. Purified
HSCs were obtained using a modification of the methods
described by Spangrude et al. [14]. BM cells were stained
sequentially as follows: (a) cells were incubated with lin-
eage marker rat-anti-mouse antibodies to B220(RA3-6B2),
CD4(GK-1.5), CD8(53.6.72), Gr-1(RB6-8C5), Mac-
1(M1/70.15.11.5.) and ery t h rocytes (antibody TER119);
(b) the washed cells were incubated with phycoery t h r i n -
conjugated goat antiserum to rat immunoglobulin and
then washed through an FCS cushion; (c) the washed cells
w e re incubated in 20% normal rat IgG to block Fc binding
sites, followed by addition of biotin-labeled rat antibody to
Sca-1 (antibody E13 161-7); (d) the cells were again
washed through an FCS cushion and then incubated with
s t reptavidin-conjugated MACS beads (Miltenyi Biotec,
A u b u rn, CA) and fluoroscein-conjugated mouse antibody
to Thy-1.1 (antibody 19XE5); (e) Texas re d - c o n j u g a t e d
avidin (Cappel, West Chester, PA) was added 10 minutes
after adding beads; (f) cells were washed for the last time
with HBSS solution and were centrifuged for cell suspen-
sion; (g) after the final wash, the cell suspension was fil-
t e red through a nylon mesh and passed through a MACS
s t reptavidin-conjugated magnetic bead column to pre -
enrich for Sca-11 cells; (h) cells obtained from the column
w e re washed and resuspended and 1 mg/mL pro p i d i u m
iodide (PI; Sigma, St. Louis, MO) was added. In order to
obtain a population highly enriched for Lineage– / l o,
T h y 1 . 1l o, and Sca-l1 cells, the Sca-11–enriched cells were
analyzed and then sorted on a dual laser Vantage sort e r
(made available through the FACS shared-user group at
S t a n f o rd University). Dead cells were excluded from analy-
sis by PI staining. After sorting, the sorted fraction was
reanalyzed by FACS. Antibodies for HSC purification
w e re kindly provided by Dr. I. We i s s m a n .
Injections of designated numbers of purified HSCs or
BM (approximately 0.1 mL/injection) were via tail vein.
With rare exceptions, each HSC inoculum was tested bio-
logically by injection of 100 or 200 cells into lethally
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i rr adiated syngeneic or congenic hosts, which were sacri-
ficed for day-12 spleen colony forming–unit assay (CFU-S)
analysis. In all experiments, 3–10 CFU-S per 100 cells
injected were obtained on day 12, indicating functional
HSC activity in the injected inocula.
Isolation of GVT - c o n fe r ring candidate cell populations
To obtain purified lineage-specific cells from BM and
spleen, a combination of magnetic bead selection and
FACS sorting was used. BM and spleen cells from BA
mice were made into single cell suspensions at a concen-
tration of 108 cells/mL and were incubated with one of the
following biotin-labeled monoclonal antibodies (mAbs):
CD3e(145-2C11), CD4(H159.19), CD8(53-6.7), B220(RA3-
6B2), CD11b(M1/70), or NK1.1(PK136) (Pharmingen, San
Diego, CA). The washed cells were incubated with strepta-
vidin-conjugated magnetic beads according to the manufac-
turer’s instructions (Miltenyi Biotec). Ten minutes after the
addition of streptavidin beads, phycoery t h r i n - c o n j u g a t e d
streptavidin was added to the cell suspension. The cells were
washed and pre-enriched for the various lineages by positive
selection using MACS streptavidin-conjugated magnetic
beads. The cells were resuspended in 1 mg/mL of propid-
ium iodide, analyzed, and sorted with a dual laser Vantage.
Dead cells were excluded from analysis by propidium iodide
staining detected by the Cy5-PE channel.
Designated numbers of the isolated candidate cells were
injected via tail vein into mice that were the recipients of irr a-
diation plus BA HSCs or BA BM in the prior 24–48 hours. 
Phenotype analysis of peripheral blood or bone
m a r row
Peripheral blood was obtained from the tail vein.
Two-color immunofluorescence staining was carried out
to distinguish donor- from host-derived cells by using
mAbs specific for lineage markers for B cells (a- B 2 2 0 ) ,
myeloid cells (a- G r-1 and a-Mac-1), or T cells (a- T h y 1 . 1
and a- T h y 1 . 2 ) .
Acute GVHD
Mice were monitored post-transplantation for evidence
of acute graft-vs.-host disease (aGVHD) by weight loss, evi-
dence of ruffled fur, and/or diarrhea. 
Statistical e v a l u a t i o n
The Kaplan-Meier (KM) method was used to calculate
the probability of survival. The log-rank test was used to
c o m p a re between pairs of KM curv e s .
RESULTS
R e g r owth of lymphoma f o l l o wing syngeneic BMT
In order to establish an in vivo assay re flecting the clinical
c i rcumstance of tumor resistance and re g rowth after hemato-
poietic cell transplantation, we first determined the dose of
B C L1 cells that would constitute a re p roducibly lethal inocu-
lum within a defined time period. BALB/c mice were injected
i . v. with 103– 1 07 B C L1 cells and followed for evidence of
tumor growth as assessed by splenomegaly, the presence of
B C L1 cells circulating in peripheral blood, and death. All
doses tested proved lethal; 103– 1 05 B C L1 cells led to death in
BALB/c mice at ~5–6 weeks after injection, whereas 106– 1 07
cells led to death at ~4 weeks (data not shown). At the time of
death, inoculated mice demonstrated gross splenomegaly and
h e p a t o m e g a l y, as well as severe wasting. The lower doses of
1 03 and 104 B C L1 cells were then selected to inoculate mice.
One week later inoculated mice underwent a syngeneic BMT.
Mice were pre p a red for transplantation with lethal irr a d i a t i o n
(800 rads) and infusion of BALB/c BM at a dose of 231 06
cells per mouse. Figure 1 shows that despite lethal irr a d i a t i o n
followed by BMT, both doses of BCL1 resulted in death in a
time period not significantly diff e rent from that for BCL1-
inoculated control mice that did not receive transplants.
GVT activity of purified allogeneic HSCs vs. BM
The studies described above demonstrate the establish-
ment of a reliable model of persistence of lymphoma and
Figure 1. Survival of BCL 1-inoculated mice transplanted with syngeneic BM 
Transplant recipients were BALB/c mice inoculated with either 103 (j, n513) or 10 4 (d, n58) BCL1 cells  and 1 week later treated with lethal irradiation (8
Gy) plus i.v. infusion of 231 06 BALB/c unfractionated BM. Control BALB/c mice were inoculated with either 103 (h, n510) or 104 (s, n55) BCL1 cells
and received neither irradiation nor BM cells. Day 0 designates the day of BM transplant. 
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re g rowth following lethal irradiation and syngeneic BMT.
We next examined the GVT activity of purified allogeneic
HSCs compared with allogeneic and syngeneic unfraction-
ated BM grafts. The purified HSC population is obtained by
using phenotypic markers and the resultant rare population,
designated Thy-1 loLin–/loSca1, is devoid of mature immune
cells but give rise to all cells of the blood, including T, B,
and natural killer (NK) cells. There f o re, we tested in the
most severe model of incompatibility (MHC and mHC-mis-
match) to discover whether purified allogeneic HSC grafts
would demonstrate measurable GVT activity in vivo. 
In an earlier re p o rt [13] we showed that successful
engraftment of BA HSCs can be re p roducibly achieved in
MHC/mHC-mismatched irradiated BALB/c hosts by a dose
of 6000 Thy-1 loLin–/loSca1 cells. Here, BALB/c mice inocu-
lated with 103 B C L1 cells underwent transplantation with
lethal irradiation and infusion of either 6000 BA HSCs or
1.23107 unfractionated BA BM cells. This dose of BM was
selected because it contains an approximate calculated
equivalent of 6000 HSCs (20003). Controls for each experi-
ment included 1) BALB/c mice that received BCL1 c e l l s
only, 2) BALB/c mice that received BCL1 cells plus irradia-
tion plus 1.23107 syngeneic BM cells, and 3) BALB/c mice
that received no BCL1 tumor cells but underwent irr a d i a-
tion and transplantation with 6000 BA HSCs. Peripheral
blood chimerism was assessed by FACS analysis at 3–4 weeks
after BM/HSC transplantation.
T h ree separate experiments were perf o rmed and the
combined data are presented in Table 1 and Figure 2. Ta b l e
1 shows that all mice transplanted with allogeneic HSC or
BM were chimeric in their peripheral blood at 3 to 4 weeks
after transplantation. As we have previously re p o rted [13],
we show here that mice transplanted with purified allo-
geneic HSCs retain a significant number of host T cells and
a re there f o re mixed chimeras in the T-cell compart m e n t ,
w h e reas T cells in mice transplanted with BM are all donor
derived. The contribution of donor-derived T cells was on
average 39% and 100% for HSC and BM-transplanted
mice, re s p e c t i v e l y. Also, chimerism in the other cell lin-
eages tested (B cell, macrophage, and granulocytes) were
primarily donor derived for both HSC- and BM-trans-
planted mice (Table 1).
S u rvival of tumor-inoculated mice transplanted with
allogeneic HSCs compared with those transplanted with
unfractionated BM is shown in Figure 2A. All mice trans-
planted with allogeneic HSCs died from tumor in the same
time period as mice that received syngeneic BM (within
9 weeks following hematopoietic cell transplantation). On
n e c ropsy analysis it was noted that all mice died from the
effects of the tumor because they had massive splenomegaly
containing BCL1 cel ls and there was no evidence of
aGVHD. aGVHD was assessed by weight loss (Fig. 2B),
ru ffled fur, and diarrhea. Control mice inoculated with
B C L1 died within the same time period as mice that
received allogeneic HSCs and syngeneic BM. In contrast,
t h e re was significant survival of mice that received unfrac-
tionated allogeneic BM (p , 0.001), compared with mice in
all three control groups, and 35% of these mice were still
alive at 22 weeks post-transplantation. These data demon-
strate that purified allogeneic HSCs are devoid of GVT
activity; however, unfractionated allogeneic BM contains a
population of non-HSCs with significant GVT effects. 
Although .30% of mice that received allogeneic BM
w e re protected from BCL1 g rowth, the tumor was not
c o mpletely eliminated in these mice, but rather re m a i n e d
“ d o rmant.” Long-term surviving mice (.20 weeks post-
transplantation) were sacrificed and their splenocytes (106)
w e re transferred into unmanipulated BALB/c re c i p i e n t s .
Although spleens from the long-term surviving mice were
grossly normal and analysis by FACS staining for BCL1 with
the anti-idiotype antibody was negative, 60% of the BALB/c
recipients nonetheless developed splenomegaly and died
from BCL1-mediated disease (data not shown). 
Identification of GVT - c o n fe r ring cells in BM
The observation that a population contained within
allogeneic BM has significant GVT activity separable from
purified HSCs was somewhat surprising given the low num-
bers of mature T and NK cells resident within BM g r a f t s .
Thus, using our model we sought to identify the GVT- c o n-
f e rring population in BM to determine if this might be a
unique population. To identify the population we first stud-
ied by phenotypic analysis the content of mature immune
cells contained within unfractionated mouse BM. Table 2
shows in percentages the volume of T cells (CD31, CD41,
C D 81), B cells (B2201), macrophages (Mac-11), and NK
( N K 1 . 11) cells contained within unfractionated mouse BM.
mAb labeling and enrichment by FACS sorting after mag-
netic bead selection was then used to obtain BM cells that
w e re highly enriched for each of these populations. The
purity of these cell populations was .90% (Table 2, Fig. 3).
We next perf o rmed add-back studies in which BALB/c
mice were inoculated with 103 B C L1 cells and one week
later underwent lethal irradiation and transplantation with
6000 BA HSCs plus cotransfer of phenotypically purified
BM populations. The number of cells added back was based
on the calculated equivalent of cells of the particular phe-
notype contained in 1.231 07 BM cells (Table 2). Among
the six populations tested, only cells with CD3 or CD8
markers demonstrated significant GVT activity. Figure 4
shows that whereas the survival of the BCL1- i n o c u l a t e d
mice that received HSCs plus CD41, B2201, Mac-11, or
N K 1 . 11 cells was not significantly diff e rent compared with
the survival of control mice that received HSCs only, mice
that received HSC plus 331 05 C D 31 or 1.531 05 C D 81
cells had significantly prolonged survival rates (CD31,
p , 0.05; CD81, p , 0.001). There was no evidence of
aGVHD as determined by weight loss in mice that re c e i v e d
cotransfer of T cells (Fig. 5) or the other cell populations
(data not shown), and those mice not rescued by the cell
transplantation died from the effects of the tumor as
assessed by spleen size at necro p s y.
Table 1. Chimerism level after allogeneic HSC or BM transplantation
HSC transplantation (%) WBM transplantation (%)
T cell 39.0 100.0
B cell 100.0 100.0
Granulocytes 100.0 100.0
Macrophages 100.0 100.0
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GVT vs. aGVHD in CD3 1 and CD8 1 s p l e n o c y t e s
To determine whether peripheral T cells demonstrate
activity analogous to their BM counterparts (GVT without
aGVHD), CD31 and CD81 splenocytes were purified and
tested in add-back studies using the same protocol as that for
BM described above. Figure 6 shows the survival and body
weight curves from these mice. The outcome was markedly
d i ff e rent for mice that received CD31 splenocytes (Figs. 6A,
6C) compared with the outcome for mice that received com-
parable numbers of CD31 BM cells (Figs. 4A and Fig. 5).
W h e reas 60% of mice given 331 05 C D 31 BM cells demon-
strated p rolonged survival without evidence of aGVHD
for .20 weeks, only 20% of mice given 331 05 C D 31
splenocytes and 0% of mice given 631 05 C D 31 s p l e n o c y t e s
s u rvived beyond 12 weeks. aGVHD was responsible for the
deaths of CD31 spleen cell–inoculated mice, because most of
these mice died in the early post-transplantation phase
(Fig. 6A), prior to the deaths of control BCL1-inoculated mice,
and they demonstrated other classic signs of aGVHD includ-
ing severe weight loss (Fig. 6C), ruffled fur, and diarrhea.
In contrast to the results obtained for CD31 s p l e n o-
cytes, the majority of mice (.90%) that received CD81
splenocytes (Fig. 6B) demonstrated a markedly pro l o n g e d
s u rvival and were without evidence of aGVHD. No evidence
Figure 2. Survival and body-weight measurement of BCL 1-inoculated mice transplanted with allogeneic BM vs. HSCs 
All transplant recipients were BALB/c mice that were inoculated with 103 B C L1 cells. One week later, they received lethal irradiation (8 Gy) and either unfraction-
ated BM or purified HSCs from allogeneic BA strain mice. A. Survival post-transplantation of BA BM 1.23107 unfractionated BM (j, n515) or BA 6 0 0 0
HSCs (d, n515). As controls, mice received 1.231 07 BM from syngeneic BALB/c mice (h, n513), 103 B C L1 cells only (3, n510), or mice were transplanted
with 6000 BA HSCs but not inoculated with BCL1 (s, n520). Results were pooled from three independent experiments. B. Body weights of mice that received
either 6000 BA HSCs but no tumor (e, n55) or BA BM plus BCL1 (h; n55). Note that 3 of 5 of mice in the BM group died of tumor at around day 140. 
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of aGVHD was seen (Fig. 6D) even when the number of
C D 81 splenocyte cells was .3 times the CD81 BM dose.
The mice that died in this group had succumbed to the
effects of the tumor.
Mechanism of GVT
To understand the mechanism by which allogeneic
C D 81 cells protect mice from the B-cell lymphoma, we
used as BM donors mice that genetically lacked specific
immunologic functions. Donors were knockout mice that
w e re perforin, IL-2-, IFN-g− , or FasL-defective. All
donors had the defects bred onto the C57BL background. 
BALB/c mice were inoculated with 103 B C L1 cells and
transplanted one week later with a conditioning regimen of
lethal irradiation and then administered 1.231 07 BM cells
f rom the various donor strains. As shown in Figure 7,
unlike mice transplanted with wild-type BM, mice that
received allogeneic BM from perforin-, K.O.-, and FasL-
defective mice died within 10 weeks post-transplantation.
All mice that received BM from perforin-, K.O.-, or FasL-
defective donors had evidence of massive splenomegaly
and tumor involvement. Results from the mice that
received BM from cytokine deficient mice were more com-
plex (Fig. 7B). Although a small percentage of mice fro m
each group survived long-term, statistical analysis re v e a l e d
that their survival was not significantly diff e rent from the
syngeneic controls (IFN-g K.O., p 5 0.1663; IL-2 K.O.,
p 5 0.7727, respectively). Furt h e rm o re, necropsy analysis
revealed diff e rences in the causes of death. Table 3 shows
the spleen size and weight, an indication of tumor gro w t h ,
m e a s u red at the time of death from mice in the diff e re n t
g roups. None of the recipients of IFN-g K.O. BM had evi-
dence of splenomegaly, and although they did not develop
lethal aGVHD with severe weight loss, some of the mice
developed diarrhea. For the IL-2-K.O. BM group, the
results were more complex. A subset of mice died earlier
than the syngeneic controls without  evidence of
s p l e n o m e g a l y, whereas another subset died during the
same time period as syngeneic control mice and had
Table 2. Percentage of cell lineages in BM and purity of cells following
s o r t i n g
% cell in Purity of
unfractionated WBM after sort Number of
Cell lineage (range in %) (%) cells injected
CD3 1 2.1–4.8 96.0 3.0 310 5
CD4 1 1.9–3.5 95.7 2.0 310 5
CD8 1 0.6–1.4 91.2 1.5 310 5
B220 1 20.4–30 99.5 2.7 310 6
MAC-1 1 34–50 99.5 4.0 310 6
NK1.1 1 1.6–5.4 92.5 2.0 310 5
Figure 3. Purification of CD3 + T cells from mouse bone marrow 
CD31 T cells were purified from mouse BM by positive selection on magnetic beads followed by FACS sorting: (A) CD31 T cells represent 1.73% of unmanipu-
lated BM, (B) Enrichment of CD31 T cells to 15% after magnetic bead selection, (C) FACS profile of CD31-selected population during sorting, (D) reanalysis of
CD31 T cells after the sort shows a population which is .95% pure. 
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splenomegaly at the time of death, and a third subset that
died at .8 weeks post-transplant had very small spleens.
With the exception of the IFN-g K.O. BM re c i p i e n t s ,
none of the mice from the diff e rent groups demonstrated
evidence of aGVHD and chimera analysis of the peripheral
blood of allogeneic BM-transplanted mice surviving to 6
weeks post-transplantation showed engraftment of donor
cells (data not shown). 
In order to be certain that immune-defective mice had
peripheral T cells at levels comparable to wild-type mice,
the relative percentage of splenic immune cell subsets was
m e a s u red. As shown in Table 4, the percentage of CD81
cells from perforin and IFN-g K.O. mice did not significantly
differ from wild-type mice. However, in FasL-defective gld
mice the percentage of CD81 cells was roughly one-half
that of wild-type mice and the percentage of CD81 cells in
IL-2 K.O. spleen was approximately twice that of the wild-
type. Although there was a two-fold difference in the num-
ber of CD81 cells contained in gld BM as compared with
wild-type BM, this quantitative diff e rence was unlikely to
explain the complete lack of GVT that we observed.
These data suggest that the GVT activity of allogeneic
BM against the BCL1 lymphoma is highly dependent on
tumor cell killing via the granule-mediated and Fas
Figure 4. Co-transfer studies of allogeneic HSCs plus purified bone marrow cell subsets 
Transplant recipients were BALB/c mice inoculated with 103 B C L1 cells. One week later they received lethal irradiation (8 Gy) and 6000 BA HSCs plus purified BM
subsets. The panels show experiments comparing the survival of control mice that received BA HSCs with the survival of those that received BA HSCs plus the specifie d
populations as follows: (A) HSCs only (j, n55) as opposed to HSCs and 331 05 C D 31 T cells (s, n55); (B) HSCs only (j, n55) as opposed to 1.531 05 C D 81 T
cells (s, n58); (C) HSCs only (j, n55) as opposed to 231 05 C D 41 T cells (s, n55); (D) HSCs only (j, n55) as opposed to 2.731 06 B 2 2 01 cells (s,
n55); (E) HSCs only (j, n55) as opposed to 431 06 M a c - 11 cells (s, n55); (F) HSCs only (j, n510) as opposed to 231 05 N K 1 . 11 cells (s, n510). 
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p a t hways, whereas there may be partial contribution of the
cytokine IL-2 to achieve optimal tumor protection. The
role of IFN-g in GVT is unclear, but it may provide a pro-
tective effect against GVHD. 
DISCUSSION
In this study we developed a preclinical model for per-
sistence and relapse from lymphoma following syngeneic
BMT to formally test if allogeneic HSCs have measurable
GVT effects. Since HSCs are a primitive population of
immunologically naive cells, our expectations were that the
allogeneic HSC grafts would not demonstrate GVT activity.
In fact, this is what was observed. Unresponsiveness to the
lymphoma BCL1 o c c u rred even when the mismatch was
between MHC plus mHC disparate donor and host—a situ-
ation that should allow for maximal recognition of tumor
alloantigens. In contrast, unfractionated BM had significant
anti-tumor activity. This observation was somewhat surpris-
ing given that, unlike human BM, mouse BM is devoid of
peripheral blood contamination and there f o re contains a
relatively low content of mature immune cells. 
Thus, we sought to identify the phenotype and function
of the GVT- c o n f e rring population contained in BM. We
F i g u r e 5. Body weights of mice that r e c e i v ed allog e n e i c
HSCs plus purified BM T cell subsets 
B C L1 tumor–inoculated recipient BALB/c mice transplanted with HSCs plus
T-cell subsets as described in Figure 4 were monitored for evidence of aGVHD
by body weight. Mice were co-transferred with either purified CD31 (s) ,
C D 81 (n), or CD41 (h). Control mice received allogeneic HSCs only (3) .
Asterisks (*) indicate day that all mice in the treatment group expired from
tumor. 
Figure 6. Cotransfer studies of allogeneic HSCs plus purified spleen-cell subsets 
Transplant recipients were treated as in Figure 4 with the exception that purified CD31 and CD81 cells isolated from spleen cells were co-transferred with HSCs.
A. and C. Survival and body weights of mice that received HSC plus either 33105 CD31 (h, n59) or 63105 CD31 spleen cells (j, n59). Control mice either
received BCL1 plus HSC transplants only (d, n57) or BCL1 and no transplanted cells. B. and D. Survival and body weights of mice that received HSC plus
either 231 05 C D 81 (h, n510) or 531 05 C D 81 spleen cells (j, n510). Control mice either received BCL1 plus HSC transplants only (d, n57) or BCL1 and
no transplanted cells (3, n55). 
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found that BM T cells (CD31) conferred significant pro-
tection against the lymphoma, and further delineation into
T-cell subfractions showed that the CD81 subset contained
all the measurable GVT activity. The GVT effect of BM
T c e l l s was separable from aGVHD, since none of the mice
cotransplanted with BM CD31, CD41, or CD81 cells devel-
oped aGVHD. In contrast, cotransfer of splenocytes with
HSCs showed that although all of the GVT activity was
again isolatable to the CD81 fraction and these cells did not
cause aGVHD, splenic CD31 cells caused lethal aGVHD at
doses equivalent (331 05/mouse) to that administered for BM
C D 31 cells. The latter results suggest that functional diff e r-
ences exist between BM and splenic CD31 cells in inducing
GVHD, and agree with prior studies [24,25] demonstrating
that BM, when compared to peripheral lymphoid org a n s ,
contains a higher pro p o rtion of T-cell subsets capable of sup-
p ressing GVHD. Such “natural suppressor” cells expre s s
CD3 and the a/ β T-cell receptor but do not express CD4 or
CD8. Furt h e rm o re, a more recent study [26] has demon-
strated that BM contains a significantly higher percentage of
N K 1 . 11-T cells, and such cells, re g a rdless of whether they
e x p ress the CD4 or CD8 coreceptors, suppressed aGVHD. 
The ability of CD81 cells to protect BCL1- i n o c u l a t e d
mice from tumor growth appears to be dependent upon
killing of tumor targets either via perforin-mediated cytolysis
and/or by the FasL pathway, because allogeneic donor BM
cells defective in either of these functions conferred no tumor
p rotection. In the present studies we noted that the tumor
was not completely eradicated in BCL1- p rotected re c i p i e n t s ,
because splenocytes from these mice could still transfer
Figure 7. Survival of BCL 1-inoculated mice transplanted with allogeneic BM from immune defective mice 
All transplant recipients were BALB/c mice inoculated with 103 B C L1 cells. One week later they received lethal irradiation (8 Gy) and unfractionated BM from the
following immune-defective mice: (A) perforin K.O. (s, n=10), FasL defective (m, n=10), and (B) IL-2 K.O. (m, n=15), IFN-γ K.O. (s, n=7). Control mice
received wild-type allogeneic C57BL/6J BM (j, n=17) or syngeneic BALB/c BM (e, n=10). All allogeneic donor mice were of the C57BL/6J background.
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d i sease into BALB/c recipients. That BCL1 can enter a state
of “tumor dormancy” under defined host conditions has been
extensively studied by Vitetta and Uhr [27–29] and others
[30,31]. In those studies where BCL1 d o rmancy occurred in
the context of an allogeneic BMT [29,32] the pro p o s e d
mechanism of tumor suppression was via cytokines or alter-
ations in the host micro e n v i ronment. However, the effect of
p e rforin FasL was not examined in those re p o rts. 
The role of the cytokines IFN-g and IL-2 appears to be
more complex. Although recipients of IFN-g K.O. BM were
tumor protected, they nonetheless died several weeks post-
transplantation. Some of the mice developed diarrh e a ,
although not overt wasting. The possibility that IFN-g K.O.
BM recipients suffered from aGVHD is consistent with the
re p o rt by Yang, et al. [33] that showed protection fro m
GVHD by IL-12 appears to be dependent upon the ability
of the donor cells to produce IFN-g.
A dominant role for unprimed CD81 cells in resistance
to BCL1 [34,35] as well as other tumors [36–38] has been
re p o rted by others. In fact, in most models CD81 c e l l s
appear to be the primary mediators of GVT activity. A
major reason that such studies have not been extrapolated to
the clinical setting is the existence of earlier data which sug-
gest that CD81 cells are also the primary mediators of
aGVHD in MHC-matched BMT [39,40]. In the classic
experiments by Korngold and Sprent [40] in which different
MHC-matched mouse strain combinations were studied to
d e t e rmine if GVHD is mediated by CD81 or by CD41
cells, the results from most strain combinations suggested
that CD81 cells predominate in GVHD responses. Using
purified HSCs and cotransferred CD81 cells, we have
recently re p roduced one of those strain combinations and
obtained a different outcome. In contrast to the earlier data
which showed a high level of mortality from aGVHD by 8
weeks post-transplantation using CD81 (Lyt-21) lymphnode
cells, we did not encounter lethal GVHD using equivalent
numbers of purified CD81 splenocytes. The reasons for the
c o n flicting results are unclear; however, potential explana-
tions include diff e rences in the way the CD81 cells were
purified and the source of peripheral CD81 cells. 
In our experiments, unmanipulated CD81 T cells clearly
play the central role in resistance to BCL1; h o w e v e r, we do
not exclude the possibility that other subsets can part i c i p a t e
in tumor resistance, particularly those that have underg o n e
ex v i v o activation. Indeed, in collaborative studies with
R. Negrin we have determined that a population of mouse
splenocytes cultured several weeks under the influence of IL-2 ,
I F N -g, and a-CD3 mAbs give rise to a population of cells
that when cotransferred with donor-matched allogeneic
HSCs protect mice from BCL1 disease and do not cause
aGVHD (manuscript in preparation). This activated cell pop-
ulation expresses T-cell (CD3, a/b T-cell re c e p t o r, CD8)
markers and a subset also expresses NK-cell markers (NK1.1)
[41]. Fowler et al. [42] have determined that cultured CD81
T cells made to diff e rentiate into either Tc1 or Tc2 types
under the influence of IL-12 and IL-4, re s p e c t i v e l y, still
demonstrate GVT activity (Tc1 . Tc2) with reduced GVHD
when given a relatively high doses and compared with unfrac-
tionated CD81 cells. Although in our studies we found no
GVT activity in the NK1.1 purified fraction, IL-2-activated
NK cells from allogeneic donors have been pre v i o u s l y
re p o rted to demonstrate potent GVT activity against
leukemias [7,43,44], and other tumor types [37,45–48].
In summary, the many technical advances made in the
field of cell selection now make it possible to perf o rm clinical
B M Ts of defined cell composition. Yet the current standard
practice of allogeneic BMT is to infuse unmanipulated BM
grafts or, in the event of leukemia or lymphoma relapse, to
infuse unmanipulated donor lymphocytes. Because prior
re p o rts have indicated that CD81 cells may be the primary
mediators of GVHD in an MHC-matched transplantation, it
is controversial as to whether CD41 as opposed to CD81
cells should be re t u rned with purified HSC grafts. However,
re g a rdless of whether CD41 cells or CD81 cells are believed
Table 3. Spleen weight and length posttransplantation with K.O. mouse BM
Balb/c pfp gld IFN- g IL-2
Wk post-BMT Weight (g)/length (cm) Weight (g)/length (cm) Weight (g)/length (cm) Weight (g)/length (cm) Weight (g)/length (cm)
0–5 — — — — — — 0.07 6 0.03 1.03 6 0.21 0.035 6 0.01 1.25 6 0.15
6–10 0.1 6 0.02 1.0 6 0.15 0.85 6 0.11 3.5 6 0.12 1.01 6 0.07 3.5 6 0.09 0.21 6 0.12 1.8 6 0.35 0.55 6 0.12 2.8 6 0.26
11– — — — — — — — — 0.04 6 0.01 1.5 6 0.15
Table 4. Percentage of cell lineages in unfractionated K.O. mice BM
Percentage of lineage in unfractionated BM
Cell lineage Wild-type Fas defective (gld) Perforin K.O. IFN- g K.O. IL-2 K.O.
CD3 + 3.7 6 0.08 2.0 6 0.21 1.9 6 0.14 3.3 6 1.24 6.5 6 0.00
CD4 + 1.55 6 0.04 1.45 6 0.25 1.14 6 0.16 1.6 6 0.33 4.75 6 0.75
CD8 + 1.35 6 0.04 0.68 6 0.24 1.2 6 0.15 1.7 6 0.91 2.95 6 0.05
NK1.1 + 2.05 6 0.45 0.95 6 0.75 2.35 6 0.15 1.89 6 0.39 2.85 6 0.05
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to be more important in mediating GVHD, it is clear fro m
many preclinical models that the combination of the two
populations exacerbates GVHD more than either subpopula-
tion alone. In our studies, at the CD81 cell doses tested that
c o n f e rred significant GVT activity, we did not observe evi-
dence of lethal aGVHD. Furt h e rm o re, although in the cur-
rent studies we focused on the benefits of such CD81 cells for
GVT effects, there is ample evidence that CD81 cells can
also facilitate the engraftment of purified HSC populations
[49–51]. Thus, we favor an approach to allogeneic hemato-
poietic cell transplantation wherein titrated numbers of
C D 81 cells should be cotransferred with purified HSC/pro-
genitor populations—an approach that is currently clinical
feasible. 
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